Highlander Partners’s Bristol-Myers Squibb BMY Stock Holding History

Highlander Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-60,000	Closed	-$3.08M	–	42
2023 Q4	$3.08M	Hold	60,000	–	–	2.46%	13
2023 Q3	$3.48M	Hold	60,000	–	–	3.44%	9
2023 Q2	$3.84M	Hold	60,000	–	–	4.31%	8
2023 Q1	$4.16M	Hold	60,000	–	–	5.63%	6
2022 Q4	$4.32M	Hold	60,000	–	–	5.85%	7
2022 Q3	$4.26M	Hold	60,000	–	–	6.35%	7
2022 Q2	$4.62M	Sell	60,000 -40,000	-40%	-$3.05M	6.08%	7
2022 Q1	$7.3M	Hold	100,000	–	–	9.16%	3
2021 Q4	$6.24M	Buy	+100,000	New	+$5.87M	7.6%	5

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Highlander Partners's BMY Position: Q1 2024 in Review

Highlander Partners sold out of Bristol-Myers Squibb (BMY) in Q1 2024, closing a stake of 60,000 shares — an estimated $3.08M sold.

Highlander Partners first reported a position in BMY in Q4 2021 and held it in 9 quarters. The position peaked at $7.3M in Q1 2022. 2,338 funds tracked by Wall St. Rank hold BMY as of Q1 2024.

Highlander Partners reported no remaining Bristol-Myers Squibb position as of Q1 2024 after selling out during the quarter.
Highlander Partners sold 60,000 Bristol-Myers Squibb shares in Q1 2024, an estimated $3.08M.
Highlander Partners first reported a position in Bristol-Myers Squibb in Q4 2021 and held it in 9 quarters.
Highlander Partners's Bristol-Myers Squibb position peaked at $7.3M in Q1 2022.
2,338 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2024.

Based on Highlander Partners's 13F filing for Q1 2024, filed 1 May 2024.